For help on how to get the results you want, see our search tips.
677 results
Medicine
Periodic safety update report single assessments Remove Periodic safety update report single assessments filter
Orphan designations Remove Orphan designations filter
Orphan designation status
Withdrawn Remove Withdrawn filter
-
List item
Orphan designation: allogeneic peripheral blood mononuclear cells incubated ex-vivo with 16, 16-dimethyl prostaglandin E2, dexamethasone for: Treatment in haematopoietic stem cell transplantation (updated)
Date of designation: 10/08/2022, Withdrawn, Last updated: 10/08/2022 -
List item
Orphan designation: Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan (avalglucosidase alfa) for: Treatment of glycogen storage disease type II (Pompe's disease) (updated)
Date of designation: 26/03/2014, Withdrawn, Last updated: 02/08/2022 -
List item
Orphan designation: Moxetumomab pasudotox for: Treatment of B-lymphoblastic leukaemia/lymphoma (updated)
Date of designation: 19/07/2022, Withdrawn, Last updated: 25/07/2022 -
List item
Orphan designation: Teclistamab for: Treatment of multiple myeloma (updated)
Date of designation: 19/07/2022, Withdrawn, Last updated: 22/07/2022 -
List item
Orphan designation: arimoclomol citrate for: Treatment of inclusion body myositis (updated)
Date of designation: 18/07/2022, Withdrawn, Last updated: 19/07/2022 -
List item
Orphan designation: Arimoclomol for: Treatment of amyotrophic lateral sclerosis (updated)
Date of designation: 18/07/2022, Withdrawn, Last updated: 19/07/2022 -
List item
Orphan designation: Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1 (naratuximab emtansine) for: Treatment of diffuse large B-cell lymphoma (updated)
Date of designation: 18/07/2022, Withdrawn, Last updated: 19/07/2022 -
List item
Orphan designation: Melphalan flufenamide for: Treatment of plasma cell myeloma
Date of designation: 19/03/2015, Withdrawn, Last updated: 08/07/2022 -
List item
Orphan designation: Human autologous mesenchymal adult stem cells extracted from adipose tissue for: Treatment of anal fistula
Date of designation: 26/08/2005, Withdrawn, Last updated: 01/07/2022 -
List item
Orphan designation: Chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked oligonucleotide inhibitor directed against microRNA-155-5p for: Treatment of cutaneous T-cell lymphoma
Date of designation: 22/05/2017, Withdrawn, Last updated: 22/06/2022 -
List item
Orphan designation: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate (riociguat) for: Treatment of pulmonary arterial hypertension
Date of designation: 20/12/2007, Withdrawn, Last updated: 14/06/2022 -
List item
Orphan designation: (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride) for: Treatment of primary sclerosing cholangitis
Date of designation: 16/01/2014, Withdrawn, Last updated: 14/06/2022 -
List item
Orphan designation: (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride) for: Treatment of primary biliary cirrhosis
Date of designation: 16/01/2014, Withdrawn, Last updated: 14/06/2022 -
List item
Orphan designation: Trifarotene for: Treatment of autosomal recessive congenital ichthyosis
Date of designation: 24/03/2020, Withdrawn, Last updated: 07/06/2022 -
List item
Orphan designation: Inebilizumab for: Treatment of neuromyelitis optica spectrum disorders
Date of designation: 20/03/2017, Withdrawn, Last updated: 19/05/2022 -
List item
Orphan designation: synthetic human hepcidin for: Treatment of sickle cell disease
Date of designation: 18/11/2016, Withdrawn, Last updated: 18/05/2022 -
List item
Orphan designation: Synthetic hepcidin for: Treatment of beta thalassaemia intermedia and major
Date of designation: 09/10/2015, Withdrawn, Last updated: 18/05/2022 -
List item
Orphan designation: Obeticholic acid for: Treatment of primary sclerosing cholangitis
Date of designation: 16/03/2014, Withdrawn, Last updated: 10/05/2022 -
List item
Orphan designation: N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide (mocetinostat) for: Treatment of Hodgkin's lymphoma
Date of designation: 14/09/2007, Withdrawn, Last updated: 10/05/2022 -
List item
Orphan designation: N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide (mocetinostat) for: Treatment of acute myeloid leukaemia
Date of designation: 31/01/2008, Withdrawn, Last updated: 04/05/2022 -
List item
Orphan designation: Lisocabtagene maraleucel for: Treatment of primary mediastinal large B-cell lymphoma
Date of designation: 19/11/2018, Withdrawn, Last updated: 04/05/2022 -
List item
Orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel) for: Treatment of follicular lymphoma
Date of designation: 25/05/2018, Withdrawn, Last updated: 04/05/2022 -
List item
Orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel) for: Treatment of diffuse large B-cell lymphoma
Date of designation: 17/07/2017, Withdrawn, Last updated: 04/05/2022 -
List item
Orphan designation: Allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19 for: Treatment in haematopoietic stem cell transplantation
Date of designation: 27/06/2016, Withdrawn, Last updated: 07/04/2022 -
List item
Orphan designation: Rimiducid for: Treatment of graft-versus-host disease
Date of designation: 30/05/2016, Withdrawn, Last updated: 07/04/2022